A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

Wu Y.-L.Tsuboi M.John T.Grohe C.Majem M.Goldman J.W.Laktionov K.Kim S.-W.Kato T.Vu H.-V.Lu S.Lee K.-Y.Akewanlop C.CHONG-JEN YUDe Marinis F.Bonanno L.Domine M.Shepherd F.A.Zeng L.Hodge R.Atasoy A.Rukazenkov Y.Herbst R.S.2022-06-272022-06-2720211479-6694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120636168&doi=10.2217%2ffon-2021-0752&partnerID=40&md5=cf27ce30b9af78e6c988dd1915396fb5https://scholars.lib.ntu.edu.tw/handle/123456789/613978A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerjournal article10.2217/fon-2021-0752347236342-s2.0-85120636168